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The initial step in a humoral immune response
involves the acquisition of antigens by B cells
via surface immunoglobulin. Surprisingly, ana-
tomic studies indicate that lymph-borne pro-
teins do not have access to the follicles where
naive B cells reside. Thus, it is unclear how B
cells acquire antigens thatdrain to lymphnodes.
By tracking a fluorescent antigen and a pepti-
de:MHC II complex derived from it, we show
that antigen-specific B cells residing in the folli-
cles acquire antigen within minutes of injection,
first in the region closest to the subcapsular
sinus where lymph enters the lymph node. Anti-
gen acquisition, presentation, and subsequent
T cell-dependent activation did not require B
cell migration through the T cell area or expo-
sure to dendritic cells. These results indicate
that the humoral response is initiated as soluble
antigens diffuse directly from lymph in the sub-
capsular sinus to be acquired by antigen-spe-
cific B cells in the underlying follicles.
INTRODUCTION
Naive B cells enter lymph nodes from the blood through
the high endothelial venules (HEV), migrate across the T
cell area, and spend about 24 hr in the follicles before
exiting through the efferent lymph and returning to the
circulation (Goodnow, 1997). Upon encountering antigen,
B cells expressing antigen-specific Ig molecules increase
expression of the chemokine receptor, CCR7, andmigrate
to the border between the follicle and T cell area, where
they present antigen-derived peptides in the context of
MHC II molecules to antigen-specific CD4+ T helper cells
(Garside et al., 1998; Okada et al., 2005; Reif et al., 2002).
The antigen-specific B cells then receive signals from the
helper T cells, proliferate, and undergo isotype switching
(Jacob et al., 1991; MacLennan et al., 1997; Pape et al.,
2003). Some of the activated progeny become extrafollic-
ular antibody-secreting plasma cells while others entergerminal centers, where they undergo somatic mutation
to generate high-affinity memory B cells and long-lived
plasma cells (Kelsoe, 1996; Vinuesa et al., 2005).
Recent work has shed light on the anatomic process
that leads to peptide:MHC II complex recognition and
helper T cell activation in lymph nodes. Protein antigens
from microbes or vaccines that are present in the subcu-
taneous tissue flow through afferent lymphatics into the
subcapsular sinuses of the draining lymph node (Catron
et al., 2004; Itano and Jenkins, 2003). Experiments track-
ing injected labeled antigens by microscopy have shown
that soluble antigen does not freely percolate from the
subcapsular sinuses through the T cell area and follicles
(Gretz et al., 1997, 2000). Instead, it is channeled through
enclosed conduit tubes (Sixt et al., 2005), which are com-
posed of collagen fibers wrapped in a layer of fibroblastic
reticular cells (FRCs) (reviewed by von Andrian and Mem-
pel, 2003). The conduits form a complex network that
physically connects the space around the HEV to the
sinuses. Lymph node-resident dendritic cells (DCs) phys-
ically interact with the conduits to acquire soluble antigen
(Bajenoff et al., 2003; Sixt et al., 2005), and DCs in the sub-
cutaneous tissue pick up antigen, migrate into the sub-
capsular sinus, and squeeze between the cells of the sinus
floor to reach the T cell area where antigen presentation
to T cells occurs (Cavanagh and Von Andrian, 2002; Itano
and Jenkins, 2003).
It is less clear how follicular B cells acquire their cognate
antigen. The conduit network is relatively sparse in the fol-
licles compared to the T cell area. In addition, soluble an-
tigen leaking from the conduits into the follicles has not
been observed. Thus, the restrictions imposed on soluble
antigen by the conduit network would appear to be signif-
icant barriers to antigen acquisition by the vast majority of
naive B cells, which reside in the follicles.
A recent body of literature supports an indirect mecha-
nism by which B cells acquire antigen from DCs that take
up antigen via the inhibitory Fc receptor FcgRIIB andmain-
tain it in an unprocessed form for recycling to the cell sur-
face (Bergtold et al., 2005; Delamarre et al., 2005). Several
groups have described interactions between DCs and B
cells and demonstrated that DCs can regulate B cell
responses both in vitro and in vivo (Balazs et al., 2002;
Dubois et al., 1997; Lindquist et al., 2004; MacphersonImmunity 26, 491–502, April 2007 ª2007 Elsevier Inc. 491
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B cells enter lymph nodes and migrate across the T cell
area, they may encounter resident DCs that acquired
soluble antigens from the conduits or migrant DCs that
acquired antigens from the tissue injection site. After rec-
ognizing unprocessed antigen on the DCs, B cells migrate
from the T cell area directly to the T-B border to receive T
cell help (Qi et al., 2006). Alternatively, some DCs have
been shown to migrate into B cell follicles, and thus could
potentially carry antigen to antigen-specific B cells resid-
ing in the follicles (Berney et al., 1999; Martinez-Pomares
et al., 1996).
Another possibility is that antigen-specific B cells enter
a draining lymph node from the blood and acquire soluble
antigen directly when passing through the perivenular
space of the HEV. If this were the exclusive mechanism
by which B cells acquire antigen, then B cells residing in
the follicle at the time of antigen injection would never
acquire antigen. Alternatively, if small amounts of antigen
can escape from the subcapsular sinus or conduits, it is
conceivable that antigen-specific B cells could acquire
it directly while residing in the follicle. Although soluble
antigen has not been detected outside conduits by light
microscopy, small (0.1–1 mm) gaps have been detected
in the floor of the subcapsular sinus by means of electron
microscopy (Clark, 1962; Farr et al., 1980; van Ewijk et al.,
1988). Thus, it is possible that small amounts of antigen,
undetectable by microscopy, leak out of these gaps and
reach antigen-specific B cells in the follicles.
We tracked antigen acquisition by antigen-specific
lymph node B cells after subcutaneous injection of a fluo-
rescent antigen to distinguish between these possibilities.
RESULTS
Tracking Antigen and Peptide:MHC II Complexes
on Antigen-Specific B Cells
To investigate the mechanism of B cell antigen acquisi-
tion, we developed a system in which antigen and pepti-
de:MHC II complexes could be tracked in vivo. To achieve
this, B cells from anti-HEL BCR transgenic knockin mice,
specific for hen egg lysozyme (HEL) (Pape et al., 2003),
were injected into C57BL/6 (B6) recipient mice. In some
experiments, TEa TCR transgenic CD4+ T cells, specific
for the Ea peptide from the I-E molecule (pEa) bound to
I-Ab (Rudensky et al., 1991), were injected along with the
anti-HEL B cells to provide help for clonal expansion and
differentiation. Recipient mice were then injected intrader-
mally in the ear with lipopolysaccharide (LPS) and a chem-
ical conjugate of HEL and recombinant EaGFP, which
contains pEa fused to Diversa green fluorescent protein
(GFP). The conjugate EaGFP-HEL contains some free
EaGFP and some monovalent conjuate, with a molecular
weight of 45 kDa, but mostly consists of a variety of larger
multivalent conjugates, with molecular weights of 70 kd
and greater (data not shown).
Flow cytometry was used to track endogenous B cells,
DCs, and transgenic anti-HEL B cells. Endogenous B cells
were identified with anti-B220, DCs with anti-CD11c, and492 Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc.the anti-HEL B cells via HEL binding, anti-HEL, and intra-
cellular staining with an antibody specific for the IgMa allo-
typic determinant present in the anti-HEL Ig heavy chains,
but not in Ig heavy chains of B6 origin (Figure 1A). Antigen
uptake was assayed by green fluorescence, and antigen
presentation was monitored with the Y-Ae monoclonal
antibody, which is specific for pEa:I-Ab complexes
(Rudensky et al., 1991).
B Cells Acquire Antigen and Present Peptide:MHC II
Complexes More Efficiently than DCs
To determine the sensitivity of the three cell types,
amounts of antigen and peptide:MHC II complex were
measured 24 hr after injection of various doses of conju-
gate antigen (Figures 1B–1D). Anti-HEL B cells acquired
antigen and presented peptide:MHC II complexes after
immunization with as little as 0.3 mg of conjugate antigen
(Figure 1B), whereas antigen uptake and production of
peptide:MHC II complexes by endogenous B cells and
DCswas detected only at the highest dose (30 mg) (Figures
1C and 1D). In addition, the anti-HEL B cells produced 50-
fold more peptide:MHC II complexes at the 30 mg dose
than endogenous B cells (based on mean flourescense
intensity) and showed a dramatic decrease in anti-HEL
BCRexpression, ameasure of BCRoccupancy (Figure 1E;
Fulcher et al., 1996). In contrast, anti-HEL B cells, endog-
enous B cells, and DCs all produced similar amounts of
antigen and peptide:MHC II complexes after injection of
30 mg of unconjugated EaGFP, confirming that binding
of the anti-HEL BCR to HEL enhances the efficiency of
antigen uptake and presentation by the antigen-specific
B cells.
The kinetics of antigen acquisition by antigen-specific B
cells were assessed to determine whether the higher sen-
sitivity of these B cells resulted in quicker antigen uptake.
Surprisingly, as early as 10 min after injection of 30 mg of
conjugate antigen, all of the anti-HELB cells in the draining
lymph node had high amounts of antigen (Figure 2A). An-
tigen remained high in the anti-HEL B cells at 4 hr and
declined thereafter, presumably reflecting antigen inter-
nalization and processing. However, some processing of
antigen must have occurred prior to the 4 hr time point
because presentation of peptide:MHC II complexes on
the anti-HEL B cells was readily detectable at this time.
Peptide:MHC II complex expression on the anti-HEL B
cells peaked at 24 hr and then declined rapidly by 48 hr
and 72 hr, suggesting that the actively proliferating anti-
HEL B cells were unable to acquire and present additional
antigen beyond 24 hr after injection (Figure 2A).
In contrast to antigen-specific B cells, DCs had much
lower amounts of antigen at 10 min and 4 hr after injection
(Figure 2B). Furthermore, by 4 hr the amounts of pepti-
de:MHC II complexes on DCs were much lower than the
amounts on anti-HEL B cells. Only at the 24 hr time point
did a population of DCs arise with the amount of antigen
and peptide:MHC II complexes comparable to the anti-
HEL B cells. However, these DCs have been previously
shown to bemigrants from the injection site, and therefore
did not acquire antigen in the draining lymph node (Itano
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B6 mice injected intravenously with 2 3 106 anti-HEL B cells were later injected intradermally with various amounts of EaGFP-HEL or unconjugated
EaGFP plus LPS. Antigen acquisition and peptide:MHC II expression by anti-HEL B cells, endogenous B cells, and DCs in the draining cervical lymph
nodes were measured 24 hr later.
(A) Representative flow cytometric analysis showing the gating of endogenous B220+ B cells (right plot, left gate), CD11c+ DCs (circular gate), and
anti-HEL B cells (right plot, right gate).
(B–D) Peptide:MHC II complexes (Y-Ae) and GFP antigen is shown on representative gated populations indicated to the left of the plots. Numbers
represent the percentages of cells that fall in each quadrant.
(E) BCR expression on gated anti-HEL B cells, with the mean fluorescence intensity indicated on the histogram.et al., 2003). Thus, DCs present in the lymph node at
the time of antigen injection acquired less antigen and
presented lower amounts of peptide:MHC II complexes
than antigen-specific B cells.Soluble Antigen Flows Directly to B Cell Follicles
within Minutes after Intradermal Injection
The observation that anti-HEL B cells acquired antigen 10
min after injection was surprising in light of previous work,Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc. 493
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Acquisition of Antigen by Follicular B CellsFigure 2. Kinetics of Antigen Acquisition and Peptide:MHC II Production by Anti-HEL B Cells and DCs
B6 mice injected with 23 106 anti-HEL B cells and 23 106 TEa T cells were later injected with 30 mg EaGFP-HEL plus LPS. Draining cervical lymph
nodes were harvested at the indicated time points after antigen injection for flow cytometry. Peptide:MHC II complexes (Y-Ae) and GFP antigen
are shown on (A) anti-HEL B cells or (B) DCs that were gated as described in Figure 1. Numbers represent the percentages of cells that fall in
each quadrant. Data are representative of two independent experiments.demonstrating that soluble antigens are confined to the
subcapsular sinus and conduit network of the lymph
node (Gretz et al., 2000; Ingulli et al., 2002; Itano and
Jenkins, 2003; Sixt et al., 2005). However, because these
studies involved rehydrated tissue sections, it was possi-
ble that non-cell-associated antigen may have washed
away. We revisited this issue with this concern in mind.
Mice were injected with purified 5-(and-6)-(((4-chloro-
methyl)benzoyl)amine)tetramethylrhodamine (CMTMR)-la-
beled polyclonal B cells and 7-amino-4-chloromethylcou-
marin (CMAC)-labeled polyclonal T cells (Figures 3A–3D)
to mark the T cell area and B cell follicles. Cryo-sections
of draining lymph nodes of recipient mice injected with
30 mg of conjugate antigen were flash frozen, sectioned,
and examined immediately by fluorescence microscopy,
without hydration, to prevent the loss of soluble antigen.
Fluorescent antigen was undetectable after PBS injection
but was readily detected in a diffuse pattern in the subcap-
sular andconnected sinusesat 30 s and3.5min and in some
of the follicles at 3.5 min after antigen injection (Figures 3B
and 3C). Interestingly, the diffuse pattern of green antigen
was not detected in the T cell area at these time points or
at 10–30 min after antigen injection (data not shown). By
2 hr after injection, the diffuse green antigen had disap-
peared, leaving antigen mostly in the sinuses (Figure 3D),
as observed in earlier work (Gretz et al., 2000; Itano and
Jenkins, 2003). Quantitatitative image analysis at the 3.5
min time point demonstrated that more antigen reached
the follicles than T cell areas (Figure 3E). Thus, this ap-
proach produced the unexpected result that antigen flows
rapidly into the follicles in an outside-in direction.
These results raised the possibility that antigen-specific
B cells acquire antigen in the follicles as it diffuses from the
sinuses. This possibility was tested by tracking anti-HEL B
cells in lymph node sections from recipients injected with494 Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc.a lower, and thus more physiologically relevant, dose of
3 mg of green conjugate antigen. Tissue sections were
hydrated before antibody staining, which as mentioned
above favors the loss of free antigen. Green antigen was
not detected in the lymph nodes from mice injected with
PBS (Figure 3F). However, green antigen was readily ob-
served in the subcapsular sinuses, but not in the follicles
or T cell areas of lymph nodes from mice injected with
conjugate antigen (Figures 3G–3I). The presence of a dif-
fusing wave of antigen was evidenced by the positions
of the anti-HEL B cells that first acquired antigen. At 30 s
after injection, a few anti-HEL B cells that were very close
to the subcapsular sinus appeared yellow, indicating that
they had acquired the green antigen (Figure 3G). By 3.5
min, antigen was detected on a wider swath of anti-HEL
B cells closest to the subcapsular sinus (Figure 3H).
Anti-HEL B cells on the side of the follicle farthest from
the sinus were red, not yellow at this time, suggesting
that they had not yet taken up antigen, despite their prox-
imity to the ER-TR7 staining conduit network. By 30 min,
all of the anti-HEL B cells in the follicle had acquired anti-
gen (Figure 3I). Display of the yellow signal from these
images against a black background with an outline of
the follicle emphasized outside-in directional acquisition
of antigen (Figures 3J–3M). These data demonstrate that
anti-HEL B cells closest to the sinus acquire antigen first
as if antigen was diffusing from this location.
Late-Arriving B Cells Have Lower Amounts
of Antigen and Peptide:MHC II Complexes
Although follicular B cells acquired antigen that diffused
into the follicles from the subcapsular sinus, it remained
possible that late-arriving B cells acquire antigenwhenmi-
grating from the HEV to the follicle. This possibility was
raised by the observation that the population of anti-HEL
Immunity
Acquisition of Antigen by Follicular B CellsFigure 3. Antigen-Specific B Cells Acquire Soluble Antigen as It Enters the Follicle from the Subcapsular Sinus
(A–D) B6 mice injected with 1 3 107 CMAC-labeled polyclonal B cells and 1 3 107 CMTMR-labeled polyclonal T cells were later injected with 30 mg
EaGFP-HEL plus LPS. Draining lymph nodes were harvested, and unhydrated cryosections were examined by fluorescent microscopy. Pixels for the
T cells (blue) and B cells (red) were expanded 43 to aid in identification of the T cell areas and follicles at lowmagnification. Antigen is shown in green.
(E) Relative levels of green antigen are shown for the sinuses, follicles, and T cell areas at the 3.5min time point. Error bars represent the standard error
of the mean for 10 individual 50 3 50 mm areas from the lymph nodes shown in (A) and (C).
(F–I) B6 mice injected with 13 107 anti-HEL B cells were later injected with 3 mg of EaGFP-HEL plus LPS. Draining lymph nodes were harvested, and
cryosections were stained for anti-HEL B cells (red) and ER-TR7 (blue). Anti-HEL B cells that contain green antigen appear yellow.
(J–M) To emphasize the location of yellow B cells, the yellow pixels were enlarged and then moved to a black background. A white line defines the
follicle border. A representative follicle (out of 15–20 analyzed) is shown for each time point.B cells was heterogeneous with respect to HEL acquisi-
tion in the lymph nodes 24 hr after injection (Figure 1B).
The anti-HEL B cells with high levels of antigen and pepti-
de:MHC II complexes may have resided in the draininglymph node at the time of antigen injection, while the
anti-HEL B cells with lower antigen and complex levels
may have been cells that migrated to the draining node
at later times. This possibility was tested by preventingImmunity 26, 491–502, April 2007 ª2007 Elsevier Inc. 495
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Acquisition of Antigen by Follicular B CellsFigure 4. Late-Arriving B Cells Acquire Less Antigen than Follicular Residents
B6micewere injectedwith 23 106 anti-HEL B cells. The next day, somemicewere injectedwith anti-CD62L antibody and then immediately thereafter
with 3 mg EaGFP-HEL plus LPS, while other mice were injected with only EaGFP-HEL plus LPS. Draining lymph nodes were harvested at 24 hr after
antigen injection for flow cytometry.
(A) Peptide:MHC II complexes (Y-Ae) and GFP antigen are shown on anti-anti-HEL B cells that were gated as described in the legend to Figure 1.
Numbers represent the percentages of cells expressing high, low, or no peptide:MHC II complexes.
(B) Percentages weremultiplied by the number of live lymphocytes to obtain the total number of anti-HEL B cells expressing high (gray), low (white), or
no (black) peptide:MHC II complexes. Error bars represent the standard deviation of the mean (n = 4).B cells in the blood from entering the lymph nodes. Mice
that received anti-HEL B cells were injected with CD62L
blocking antibody and then antigen shortly thereafter.
Because anti-CD62L prevents B cells from entering the
lymph nodes from the blood, the only anti-HEL B cells in
the draining lymph nodes were those that were already
there at the time of antibody injection. When recipient
mice were treated with anti-CD62L, only anti-HEL B cells
with high levels of antigen and complex were present
(Figures 4A and 4B). Thus, the anti-HEL B cells with low
amounts of antigen and peptide:MHC II complexes were
late-arriving anti-HEL B cells that arrived in the draining
lymph node from the blood after antigen injection.
Late-Arriving B Cells Acquire Antigen
in the Absence of DC
The question remained as towhere the late-arriving B cells
acquired their antigen. Recent studies have suggested
that DCs can retain intact antigen and pass it to antigen-
specific B cells (Bergtold et al., 2005; Qi et al., 2006;
Wykes et al., 1998). Thus, it was possible that late-arriving
B cells acquired antigen from DCs while traversing the T
cell area after entering the draining lymph node through
an HEV. This possibility was tested in an experiment
where all of the anti-HEL B cells in the draining lymph no-
des of recipient mice were late-arrivers, and where DCs
could be ablated. CD11c-DTR mice, in which GFP and
diptheria toxin receptor (DTR) are expressed under the
control of the CD11c promoter (Jung et al., 2002), were
used for this purpose. Treatment of CD11c-DTR mice
with diptheria toxin (DT) eliminated 96% of CD11c+,
GFP+, DCs in the lymph nodes (Figure 5A), consistent
with previous studies (Jung et al., 2002; Zammit et al.,
2005). B6 or CD11c-DTR mice were injected with conju-
gate antigen and transferred with anti-HEL B cells 15 hr
later. 24 hr after B cell transfer, the amount of antigen
and peptide:MHC II complexes on anti-HEL B cells in
the draining lymph node were measured. The majority of
anti-HEL B cells in DC-replete B6 recipients had detect-
able amounts of antigen and peptide:MHC II complexes496 Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc.(Figure 5B). Similar amounts of antigen and peptide:MHC
II complexes were observed in anti-HEL B cells from
DT-treated B6 recipients and CD11c-DTR recipients that
were not given DT. Anti-HEL B cells in DC-ablated
CD11c-DTR recipients were not prevented from acquiring
antigen and producing peptide:MHC II complexes (Fig-
ure 5B). In fact, the anti-HEL B cells in these recipients
had higher amounts of antigen and peptide:MHC II com-
plexes than anti-HEL B cells in the DC-replete recipients,
possibly because of decreased lymph node cellularity
(Webster et al., 2006), which would effectively increase
the concentration of antigen in the lymph node. These
data demonstrate that DCs are not required for late-arriv-
ing B cells to acquire soluble antigen.
Late-Arriving B Cells Acquire Blood-Borne Antigen
before Arriving in the Draining Lymph Node
The fact that DC were not required for antigen acquisition
by late-arriving B cells raised the possibility that these
cells acquired antigen from the wave of soluble antigen
diffusing from the subcapsular sinuses. However, the tran-
sience of that wave and its failure to reach the T cell areas
raised the alternative possibility that late-arriving B cells
acquired systemic antigen before entering the draining
lymph node. To test this possibility, antigen-specific B
cells were excluded from all lymph nodes, via CD62L
blockade prior to cell transfer and subsequent injection
of antigen. In this situation, the anti-HEL B cells in the
spleen acquired antigen and expressed peptide:MHC II
complexes after subcutaneous injection of 3 but not 0.1
mg of antigen (Figure 6A). This result made it likely that
the B cells with lower amounts of antigen after injection
of 3 mg in the absence of CD62L blockade (Figure 4) actu-
ally acquired that antigen in the spleen or blood before
arriving in the draining lymph nodes. If this were the case,
then late-arriving B cells would not be expected to acquire
antigen after injection of 0.1 mg because this dose would
be too low to become systemic. To test this idea, mice
were injected with anti-HEL B cells to allow seeding of
the lymph nodes and then with or without anti-CD62L
Immunity
Acquisition of Antigen by Follicular B CellsFigure 5. Antigen-Specific B Cells Do Not Require DCs to Obtain Antigen
B6 or CD11c-DTR mice were given DT or PBS 6 hr prior to injection of 3 mg EaGFP-HEL plus LPS. A second dose of DT was administered 15 hr later,
along with a transfer of 2 3 106 anti-HEL B cells. Draining and nondraining inguinal lymph nodes were harvested 24 hr after cell transfer for flow
cytometry.
(A) CD11c staining and CD11c-GFP on gated large, MHC Class II+ cells that were enriched from nondraining inguinal lymph nodes by means of
CD11c magnetic beads.
(B) Peptide:MHC II complexes (Y-Ae) and GFP antigen are shown on gated anti-HEL B cells from the draining lymph nodes. Numbers indicate the
percentage of cells in each gate. Data are representative of four independent experiments.and the 0.1 mg dose of conjugate antigen. 24 hr later,
lymph nodes from animals that did not receive anti-
CD62L contained some anti-HEL B cells that acquired an-
tigen and produced peptide:MHC II complexes, and some
that did not (Figure 6B). In contrast, the draining lymph
node from the CD62L-blocked mouse was missing the
population of cells without antigen and peptide:MHC II
complexes. Thus, the late-arriving anti-HEL B cells ac-
quired antigen only when it was injected in a large enough
amount to access the systemic circulation. These data
imply that the antigen wave from the subcapsular sinus
moves very quickly through the follicles, because it was
not available to B cells arriving in the lymph nodes 15 hr
after injection of 0.1 mg.
Resident Follicular B Cells Constitute the Majority
of the Antibody Response
Given that resident follicular anti-HEL B cells acquired
more antigen than late-arriving B cells, it was of interest
to determine to what extent the latter population contrib-
uted to a T-dependent humoral immune response. We ex-
amined this issue under conditions of CD62L blockade
where late-arriving B cells were prevented from entering
the lymph nodes. Previous recipients of anti-HEL B cells
and SM1 CD4+ TCR Tg T cells, specific for a peptide from
Salmonella FliC in the context of I-Ab (McSorley et al.,
2002), were treated with anti-CD62L just prior to injection
of FliC-HEL conjugate antigen plus LPS. The anti-HEL B
cells, which were initially randomly distributed throughout
the follicles, migrated to the T-B border by 7 hr after anti-
gen injection both in the absence and presence of anti-
CD62L treatment (Figure 7A), confirming that follicular Bcells migrate directly to the T-B border and that movement
from the HEV through the T cell area is not required for this
phenomenon. In addition, control and anti-CD62L-treated
recipient mice had similar expanded populations of anti-
HEL IgM and IgG2a B cells and IgM and IgG2a plasma
cells 5 days after antigen injection (Figures 7B and 7C),
demonstrating that resident follicular anti-HEL B cells
were sufficient to mount a normal T-dependent response.
Even though the results with BCR transgenic B cells
showed that resident follicular B cells acquire antigen
efficiently and participate in a T-dependent immune re-
sponse, it was unclear whether endogenous polyclonal B
cells behave similarly. It was possible that too few endog-
enous antigen-specific B cells reside in the follicles of
the draining lymph node at the time of antigen injection
to mount a significant immune response. If this were true,
then the functional capabilities of the numerous adoptively
transferred follicular B cellsmay not reflect an endogenous
immune response. The ability of endogenous resident
follicular B cells in anti-CD62L-treated mice to produce
antibodies in response to subcutaneous injection of conju-
gate antigen was tested to address this possibility. The
0.1 mg dose of antigen that did not reach the blood or
spleen was used for this purpose to confine the response
to lymph nodes. Sera from control or CD62L antibody-
treated B6 mice, sacrificed 12 days after injection of
0.1 mg conjugate antigen plus LPS, were assayed for the
presence of GFP-specific IgM or IgG antibodies. In addi-
tion, sera from antigen plus LPS-injected, TCR a-deficient
mice, which have no CD4+ helper T cells, were assayed
to define the T dependence of the antibody response.
The CD62L block was very effective because 98% ofImmunity 26, 491–502, April 2007 ª2007 Elsevier Inc. 497
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Acquisition of Antigen by Follicular B CellsCFSE-labeled polyclonal B220+ B cells, injected into im-
munized mice 10 days prior to sacrifice, were prevented
from entering the draining lymph nodes of anti-CD62L-
treated mice, but not control mice (data not shown). B6
or TCR a-deficientmice immunizedwith conjugate antigen
plus LPS contained 10-fold more GFP-specific IgM than
unimmunized controls. As expected, IgG was detected in
immunized B6 mice but not in immunized TCR a-deficient
mice or unimmunized B6 mice. Surprisingly, GFP-specific
IgM and IgG antibodies were produced at near normal
amounts in immunized, CD62L antibody-treated mice,
presumably by antigen-specific B cells that were in the
lymph nodes at the time of antigen injection (Figure 7D).
The lack of a contribution to antibody production from
late-arriving B cells in this experiment is consistent with
the inability of late-arriving B cells to acquire antigen
when mice are immunized with a low dose of antigen.
DISCUSSION
Our results show that antigen-specific B cells residing in
the follicles of the draining lymph node acquire soluble an-
tigen that rapidly diffuses from the subcapsular sinuses.
Soluble antigen almost certainly reaches the subcapsular
sinuses from the injection site by passing through afferent
lymphatic vessels. Although it is conceivable that hydro-
static pressure from the injection site affected the rapidity
of this movement, the finding of Swartz et al. (1996) that
Figure 6. Late-Arriving B Cells Acquire Antigen from the
Blood
(A) Anti-CD62L-treated B6 mice were injected with 23 106 anti-HEL B
cells and then with 3 or 0.1 mg EaGFP-HEL plus LPS 24 hr later.
(B) B6mice injectedwith 23 106 anti-HEL B cells were left untreated or
treatedwith anti-CD62L and then injectedwith 0.1 mg EaGFP-HEL plus
LPS.
Spleen (A) or draining lymph nodes (B) were harvested 24 hr after
antigen injection for flow cytometry, and representative plots show
peptide:MHC II complexes (Y-Ae) and GFP antigen on gated anti-
HEL B cells. Numbers represent the percentages of cells that fall in
each quadrant.498 Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc.lymph velocity is independent of local interstitial pressure
makes it more likely that our results are a reflection of the
natural rate of lymph flow. Once in the sinus, soluble anti-
gen may diffuse into the underlying follicles through the
small (0.1–1 mm) gaps in the floor of the sinus that have
been detected by electron microscopy (Clark, 1962; Farr
et al., 1980; van Ewijk et al., 1988). Indeed, these gaps
may exist for this very purpose. Free antigen in follicles
may have been missed in earlier immunohistology studies
because it is lost during the fixation and rehydration steps
normally done before antibody staining of tissue sections
(Gretz et al., 2000; Itano and Jenkins, 2003; Itano et al.,
2003). We detected free antigen outside of the sinuses
or conduit network only on sections that were imaged
directly without hydration.
A diffusing wave of soluble antigen from the subcapsu-
lar sinus is the most likely explanation for the outside-in
nature of antigen acquisition by follicular B cells. Another
possibility was that B cells acquired antigen from the sinus
and then migrated inward. Given that antigen-positive B
cells were detected 150 mm from the subcapsular sinus
3.5 min after antigen injection, they would have had to
travel at 40 mm per minute to account for our observa-
tions. This is unlikely because antigen-engaged B cells
have been reported to migrate at only 4 mm per min
(Okada et al., 2005). In addition, all of the antigen-specific
B cells in the 150 mmband of the follicle closest to the sub-
capsular sinus acquired antigen by 3.5 min. If B cells were
picking up antigen from the sinus and then moving back
into the follicle, antigen-negative B cells on their way to
the sinus should have been observed in this band.
The conclusion that B cells acquire antigen that rapidly
diffuses into the follicles is surprising given earlier work
indicating that soluble antigens do not have free access
to the lymphocyte-rich areas of lymph nodes but rather
are contained in the conduit tubes connecting the subcap-
sular sinuses to the HEV (Gretz et al., 2000). Our finding
that proximity to the FRC network and antigen acquisition
by follicular B cells were not related suggests that B cells
do not acquire antigen from the conduits. Interestingly, the
early wave of free antigen accessed by follicular B cells did
not appear to enter the T cell area in amounts detectable
by microscopy. While it is unclear what causes this appar-
ent barrier, it may help explain why DCs in the T cell areas
must interact with the conduit network to obtain antigen
(Sixt et al., 2005).
The rapid outside-in acquisition of free antigen by follic-
ular B cellsmakes it unlikely that DCs play a role in this pro-
cess. Perhaps more surprisingly, given recent results that
B cells can acquire antigen from antigen-pulsed injected
DCs (Bergtold et al., 2005; Qi et al., 2006; Wykes et al.,
1998), we also found no evidence for a role for DCs in an-
tigen acquisition by B cells that entered the draining lymph
node after antigen injection, despite the fact that theymust
have traversed the T areaswhereDCs reside. DCsmay not
be involved under the conditions employed here because
resident DCs acquire too little antigen from the conduits
to transfer to B cells. Furthermore, our data show that by
the time late-arriving B cells enter the lymph node, they
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Acquisition of Antigen by Follicular B CellsFigure 7. Functional Consequences for Resident and Late-Arriving Antigen-Specific B Cells
B6 mice injected with 23 106 anti-HEL B cells and 13 106 SM1 T cells were left untreated or treated with anti-CD62L and then injected with 10 mg of
FliC-HEL plus LPS.
(A) Cryosections from draining lymph nodes harvested 7 hr after antigen injection show the location of endogenous B220+ B cells (blue), anti-HEL B
cells (red), and SM1 T cells (green).
(B) Representative flow cytometric analysis of draining lymph nodes 5 days after antigen injection showing staining of unswitched IgM or isotype-
switched IgG2a anti-HEL B cells. B cells with low Ig and plasma cells (PC), which have high intracellular Ig, are gated. Numbers indicate the percent-
age of cells in each gate.
(C) Percentages were multiplied by the numbers of live lymphocytes to obtain the total number of anti-HEL B cells in the draining lymph nodes 5 days
after antigen injection. An uninjected recipient control mouse contained 38 3 103 IgM anti-HEL B cells, and IgG2a anti-HEL B cells or plasma cells
were below the limit of detection. Error bars represent range of two values. Data are representative of three independent experiments.
(D) Production of serum anti-GFP Ig by endogenous B cells. B6 mice transferred with 5 3 106 TEa T cells to provide abundant CD4+ T cell help, or
TCRa KO mice, were left untreated or treated with anti-CD62L antibody and then injected with 0.1 mg EaGFP-HEL plus LPS. Serum was harvested
12 days later for the presence of anti-GFP IgM or IgG (IgG1 + IgG2a + IgG2b). Six immunized B6 mice, 2 TCRa KOmice, and an untreated B6 control
mouse were assayed, and each mouse is represented as a dot on the graphs. This experiment is representative of two independent experiments.have already acquired antigen from a systemic source,
making subsequent interactions with antigen-expressing
DCs irrelevant for this purpose. We do not argue that
DCs are dispensable for T-dependent IgG production
because DCs are important for activation of helper T cells,
which in turn are required for the production of antigen-
specific IgG by B cells. However, DCs are not required
for B cells to acquire soluble antigen and produce peptide:
MHC II complexes, the initial step in the humoral immune
response.
Our results suggest that follicular B cells are responsible
for the majority of antibody produced in lymph nodes
when antigen is limiting. This occurs because B cell-ac-cessible antigen remains localized to the draining lymph
node and disappears rapidly. This scenario is probably
relevant to vaccinations and transient localized infections.
For example, it is easy to imagine that toxins produced
during bacterial infections elicit antibody responses only
within the draining lymph nodes. Antigens from local infec-
tions may also become systemic when a microbe repli-
cates to high numbers, and in these cases, antigen-spe-
cific B cells that are present in the blood and spleen at
the time of infection would likely contribute more substan-
tially to the humoral immune response. Finally, it is impor-
tant to note that our model does not address a situation
where low amounts of antigen persist for long periods ofImmunity 26, 491–502, April 2007 ª2007 Elsevier Inc. 499
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during a persistent skin infection, because antigen would
still be present in the draining lymph nodewhen these cells
arrive.
It was remarkable that the endogenous antigen-specific
B cells that resided in the follicles of the draining lymph
nodes at the time of antigen injection were sufficient to
generate a significant antibody response. Given the low
precursor frequency of endogenous B cells, the number
of antigen-specific B cells residing in a few lymph nodes
at the time of immunization or infection would be expected
to be very small. Our findings emphasize how the localized
environment of a lymph node is highly specialized for effi-
ciently generating immune responses by small numbers of
B cells and low amounts of antigen.
Although our results suggest that DCs are not required
for soluble antigen acquisition by B cells, they may be
needed for B cells to acquire particulate or cell-associated
antigens. Thus, it will be important in the future to deter-
mine how antigen-specific B cells in lymph nodes acquire
these types of antigens, which could not diffuse from the
subcapsular sinuses.
EXPERIMENTAL PROCEDURES
Animals
6- to 8-week-old male B6 recipient mice and TCR-a KO were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). Anti-HEL
knockin mice (Pape et al., 2003), TEa TCR transgenic RAG-deficient
mice expressing the CD90.1 allele (Grubin et al., 1997), SM1 TCR
transgenic RAG-deficientmice expressing the CD90.1 allele (McSorley
et al., 2002), and CD11c-DTR mice (Jung et al., 2002) were bred on
site. DTR mice were backcrossed 10 times to B6 mice and screened
by PCR from tail DNA as previously described (Jung et al., 2002).
Mice were housed in a specific pathogen-free facility at the University
of Minnesota, and experiments were conducted according to federal
and institutional guidelines and with the approval of the University of
Minnesota Institutional Animal Care and Use Committee.
Adoptive Transfer
Pooled spleen and lymph nodes from naive TCR transgenic or BCR
knockin donor mice were prepared for adoptive transfer as previously
described (Kearney et al., 1994) and injected into the tail veins of recip-
ient mice. For some of the fluorescent microscopy studies, purified
B220+ B cells and CD4+ T cells were prepared from B6 spleen and
lymph nodes with negative selection kits from Miltenyi Biotech (Au-
burn, CA). The B220+ B cells were labeled with CMTMR (5 mM), and
the CD4+ T cells were labeled with CMAC (25 mM) at 37C for 15 min
prior to transfer (Molecular Probes, Eugene, OR).
Antigens and Injections
HEL was purchased from Biozyme Laboratories (San Diego, CA). FliC
peptide 427-441 was purchased from Invitrogen (Carlsbad, CA). Re-
combinant EaGFP was obtained from Amgen (Thousand Oaks, CA)
and utilizes DVSA Green (Diversa Corporation, San Diego, CA). The
protein was purified from bacterial lysates via a Nickel resin His-Bind
column (Novagen, San Diego, CA) as previously described (Itano
et al., 2003). HEL was chemically conjugated to FliC or EaGFP by mal-
eimide-based protein crosslinking (Pierce Biotechnology, Rockford,
IL). Lipopolysaccharide was purchased from List Biological (Campbell,
CA). Recipient mice were injected intradermally in the ear, 24 hr after
adoptive transfer of cells, with various amounts of soluble conjugate
EaGFP-HEL antigen mixed with 2 mg of LPS as an adjuvant. In some
experiments, mice received 400 mg of anti-CD62L by intraperitoneal500 Immunity 26, 491–502, April 2007 ª2007 Elsevier Inc.injection as previously described (Catron et al., 2006). Anti-mouse
CD62L was purified from supernatants of the Mel-14 hybridoma
(American Type Culture Collection, Manassas, VA) with protein G-se-
pharose. DT (Sigma, St. Louis, MO) was administered to mice by intra-
peritoneal injection at 4 ng per g body weight.
Flow Cytometry
Explanted lymph node or spleens were minced in collagenase and
EDTA solutions as previously described (Itano et al., 2003; Vremec
et al., 1992) and then passed through fine mesh, washed, and resus-
pended in culture supernantant containing 24G2 antibody (ATCC)
plus 1% mouse serum (Sigma) and 1% rat serum (Sigma) to block
Fc receptors. The resulting cell suspensions were incubated with
Pacific blue-labeled anti-CD11c, Alexa Fluor 700-labeled anti-B220
(Invitrogen), 50 mg/ml HEL (Sigma) followed by APC-labeled anti-HEL
(Mariuzza et al., 1983), biotin-labeled Y-Ae monoclonal antibody
(Rudensky et al., 1991), and PE-conjugated streptavidin (eBioscience,
San Diego, CA). The cells were then fixed in 2% formaldehyde, per-
meabilized with 0.5% saponin (Sigma), and incubated with biotin-
labeled anti-IgMa or anti-IgG2aa followed by PerCP-conjugated strep-
tavidin (BD Biosciences, San Jose, CA). For the CD11c-GFP-DTR
experiments, the efficacy of DC ablation was assessed at the endpoint
of each experiment by enriching for DCs in inguinal lymph nodes with
anti-CD11c MACS microbeads and an LS column (Miltenyi). Enriched
DCs were incubated with Pacific blue-labeled anti-CD11c and Alexa
Fluor-700-labeled anti-mouse MHC Class II antibodies (eBioscience).
Flow cytometry was performed on a LSR II device (BD Biosciences)
and analyzed with FlowJo software (Tree Star, Ashland, OR). In some
experiments, fluorescent beads (Invitrogen) were used to calculate to-
tal numbers of live lymphocytes in spleen or lymph node suspensions.
Immunohistochemistry
Whole lymph nodes were harvested and flash frozen in O.C.T. (Sakura
Finetek, Torrance, CA) freezing medium. 8–10 mm cryosections were
immediately analyzed by microscopy or fixed in 1% formaldehyde
and blocked with 1% H202, culture supernatant containing 24G2
monoclonal antibody plus 1%mouse and 1% rat serum, and avidin/bi-
otin blocking reagents (Vector, Burlingame, CA). Anti-HEL B cells were
detected with biotin-labeled anti-IgMa antibody followed by HRP-
conjugated streptavidin and TSA-direct Coumarin-tyramide or Cy5-
tyramide (Perkin Elmer, Wellesley, MA). SM1 T cells were detected with
biotin-labeled anti-Thy1.1 antibody (eBioscience) followed by HRP-
conjugated streptavidin (Perkin Elmer) and TSA-direct Cy3-tyramide
(Perkin Elmer). Endogenous B cells were detected with FITC-labeled
anti-B220 (eBioscience), and the conduit network was detected with
anti-ER-TR7 followed by biotin-labeled goat anti-rat antibody (Jack-
son Immunoresearch, West Grove, PA) and streptavidin-labeled Cy3
(Zymed, San Francisco, CA). In experiments where very early time
points were assessed, the mice were anesthetized with a mixture of
ketamine and xylazine and then injected with antigen such that the
draining lymph node could be removed and frozen within 30 s. Pictures
of lymph nodes were captured at 203 magnification with a Leica
DM5500B automated upright microscopewith a high-precisionmotor-
ized x/y stage and a Leica DFC340FX Digital Camera. Entire lymph
node images were reassembled with Leica AF6000 stitching software
(Leica, Germany) and displayed in Photoshop (Adobe, San Jose, CA).
The green background was adjusted such that a slide area without
tissue would appear black.
ELISA
Mouse sera were titrated in 96-well plates coated with 20 mg per ml
Ea-GFP and blocked with 1% BSA. Plate-bound Ig was detected by
incubating the wells sequentially with biotin-labeled IgM antibody or
a mixture of biotin-labeled IgG2a, IgG2b, and IgG1 antibodies (BD
Biosciences), HRP-labeled streptavidin, and ABTS Peroxidase Sub-
strate (KPL, Gaithersburg, MD). The titer at half-maximal OD 405
was calculated for each sample. The t test was used to compare the
means.
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